FDA Confirms Adderall Shortage
The FDA announced a shortage of the immediate release formulation of amphetamine mixed salts, also commonly known as Adderall IR, confirming reports of shortages that have been circulating about the drug which is FDA-approved to treat patients with attention deficit hyperactivity disorder (ADHD) and narcolepsy.
The FDA said one of the companies that manufactures Adderall, Teva, is experiencing intermittent manufacturing delays. Other manufacturers continue to produce the drug, but there is insufficient supply to meet U.S. market demand through those producers, the agency said.
Until supply is restored, the FDA said there are alternative therapies available for the approved indications, including the extended-release version of Adderall.